Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

598 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A multicenter, randomized, phase II/III study of dendritic cells loaded with allogeneic tumor cell lysate (MesoPher) in subjects with mesothelioma as maintenance therapy after chemotherapy: DENdritic cell Immunotherapy for Mesothelioma (DENIM) trial.
Belderbos RA, Baas P, Berardi R, Cornelissen R, Fennell DA, van Meerbeeck JP, Scherpereel A, Vroman H, Aerts JGJV. Belderbos RA, et al. Among authors: baas p. Transl Lung Cancer Res. 2019 Jun;8(3):280-285. doi: 10.21037/tlcr.2019.05.05. Transl Lung Cancer Res. 2019. PMID: 31367541 Free PMC article.
Malignant mesothelioma after radiation treatment for Hodgkin lymphoma.
De Bruin ML, Burgers JA, Baas P, van 't Veer MB, Noordijk EM, Louwman MW, Zijlstra JM, van den Berg H, Aleman BM, van Leeuwen FE. De Bruin ML, et al. Among authors: baas p. Blood. 2009 Apr 16;113(16):3679-81. doi: 10.1182/blood-2008-10-184705. Epub 2009 Feb 20. Blood. 2009. PMID: 19234144 Free article.
Switch-maintenance gemcitabine after first-line chemotherapy in patients with malignant mesothelioma (NVALT19): an investigator-initiated, randomised, open-label, phase 2 trial.
de Gooijer CJ, van der Noort V, Stigt JA, Baas P, Biesma B, Cornelissen R, van Walree N, van Heemst RC, Soud MY, Groen HJM, den Brekel AJS, Buikhuisen WA, Bootsma GP, Dammeijer F, van Tinteren H, Lalezari F, Aerts JG, Burgers JA; NVALT19 study group. de Gooijer CJ, et al. Among authors: baas p. Lancet Respir Med. 2021 Jun;9(6):585-592. doi: 10.1016/S2213-2600(20)30362-3. Epub 2021 Jan 27. Lancet Respir Med. 2021. PMID: 33515500 Clinical Trial.
Immune monitoring in mesothelioma patients identifies novel immune-modulatory functions of gemcitabine associating with clinical response.
Dammeijer F, De Gooijer CJ, van Gulijk M, Lukkes M, Klaase L, Lievense LA, Waasdorp C, Jebbink M, Bootsma GP, Stigt JA, Biesma B, Kaijen-Lambers MEH, Mankor J, Vroman H, Cornelissen R, Baas P, Van der Noort V, Burgers JA, Aerts JG. Dammeijer F, et al. Among authors: baas p. EBioMedicine. 2021 Feb;64:103160. doi: 10.1016/j.ebiom.2020.103160. Epub 2021 Jan 27. EBioMedicine. 2021. PMID: 33516644 Free PMC article.
Legal claims for malignant mesothelioma: dealing with all cases.
van der Bij S, Baas P, van de Vijver MJ, de Mol BA, Burgers JA. van der Bij S, et al. Among authors: baas p. Lung Cancer. 2013 May;80(2):153-8. doi: 10.1016/j.lungcan.2013.01.012. Epub 2013 Feb 15. Lung Cancer. 2013. PMID: 23415607
598 results